Xilio Therapeutics (XLO) Capital Expenditures (2020 - 2026)
Xilio Therapeutics (XLO) posted Capital Expenditures of $556000.0 for Q1 2026, up 2680.0% sequentially from $20000.0 in Q4 2025, and up 90.41% YoY from $292000.0 in Q1 2025.
Xilio Therapeutics (XLO) Capital Expenditures (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $556000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 90.41% year-over-year to $556000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $707000.0 (up 130.29% YoY) and the FY2025 annual result came in at $443000.0, up 1130.56% from the prior year.
- Capital Expenditures grew to $556000.0 in Q1 2026 per XLO's latest filing, from $20000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $771000.0 in Q2 2022 and troughed at -$1.3 million in Q4 2022.
- A 5-year average of $118461.5 and a median of $170000.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures plunged 372.15% in 2022, then jumped 1290.48% in 2025.
- Over 5 years, Capital Expenditures stood at -$1.3 million in 2022, then jumped by 123.6% to $316000.0 in 2023, then sank by 98.1% to $6000.0 in 2024, then soared by 233.33% to $20000.0 in 2025, then surged by 2680.0% to $556000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $556000.0, $20000.0, and $131000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | 19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19,000.00 |
| Jun 30, 2026 | 19,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 292,000.00 |
| Mar 31, 2025 | 292,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Jun 30, 2023 | 316,000.00 |
| Jun 30, 2023 | 316,000.00 |
| Mar 31, 2023 | 170,000.00 |
| Mar 31, 2023 | 170,000.00 |